

**University of Pittsburgh
School of Medicine**

CURRICULUM VITAE

BIOGRAPHICAL

Name: Heath D. Skinner
Cell Phone: (304)-641-9888
Email: skinnerh@upmc.edu
Website: www.heathskinnerlab.com
Twitter: twitter.com/HSkinnerMDPhD

Business Address:
UPMC Hillman Cancer Center
UPMC Cancer Pavilion
Suite 545
5150 Centre Avenue
Pittsburgh, PA 15232

Office Phone: 412-623-4047

EDUCATION AND TRAINING

UNDERGRADUATE

8/1996 – 6/2000	West Virginia University, Morgantown, WV	BA, 2000	Biology
-----------------	---	----------	---------

GRADUATE

8/2000 – 7/2007	West Virginia University, Morgantown, WV	MD, 2007	Medicine
-----------------	---	----------	----------

8/2000 – 7/2007	West Virginia University, Morgantown, WV	PhD, 2007	Microbiology, Immunology and Cell Biology (PI: Bing-Hua Jiang, PhD)
-----------------	---	-----------	--

POSTGRADUATE

8/2007 – 6/2008	The University of Texas at Houston Medical School, Houston, TX	Internship, 2008	Internal Medicine, (PD: Mark A. Farney, MD)
-----------------	--	------------------	--

8/2008 - 6/2012	The University of Texas MD Anderson Cancer Center, Houston, TX	Residency, 2012	Radiation Oncology (PD: Pranjan Das, MD)
-----------------	--	-----------------	---

APPOINTMENTS AND POSITIONS

7/2012 – 8/31/2018	The University of Texas MD Anderson Cancer Center, Houston, TX	Assistant Professor of Radiation Oncology
--------------------	---	--

9/1/2018 – 9/7/2018	The University of Texas MD Anderson Cancer Center, Houston, TX	Associate Professor of Radiation Oncology
---------------------	---	--

9/2018 – 2/2023	The University of Pittsburgh, Pittsburgh, PA	Associate Professor of Radiation Oncology
-----------------	---	--

7/2022 – 2/2023	The University of Pittsburgh, Pittsburgh, PA	Chair, Department of Radiation Oncology
7/2022 – 9/2024	UPMC Hillman Cancer Center	Medical Director, Clinical Radiation Oncology Network
2/2023 – present	The University of Pittsburgh, Pittsburgh, PA	Professor and Claude Worthington Benedum Chair of Radiation Oncology
9/2024 – present	UPMC Hillman Cancer Center	Chief Medical Officer, Radiation Oncology Network

CERTIFICATION and LICENSURE

SPECIALTY CERTIFICATION:

American Board of Radiology	2013 – 2026
-----------------------------	-------------

MEDICAL OR OTHER PROFESSIONAL LICENSURE:

Texas Medical Board	2011 – 2022
Pennsylvania State Board of Medicine	2018 – 2026

MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES

Society for Neuroscience	Member	1999 – 2000
American College of Physicians	Member	2000 – 2004
American Medical Association	Member	2000 – 2004
American Medical Student Association	Member	2000 – 2004
American Society of Human Genetics	Member	2002 – 2003
American Society for Radiation Oncology	Member	2008 – present
	Abstract Reviewer	2013 – present
	Member, Lung Education Committee	2021 – present
	Chair, Lung Education Committee	2022 – present
Association of Residents in Radiation Oncology	Member	2008 – 2012
Radiological Society of North America	Member	2011 – present
American Association for Cancer Research	Member	2012 – present
American Society of Clinical Oncology	Member	2014 – present
ancer Oncology	Lung Cancer Committee Member	2014 – present
	NRG-LU001 PI	2015 – present
ECOG – ACRIN	Head and Neck Cancer Committee Member	2020 – present

HONORS

- West Virginia University School of Medicine Van Lier Research Convocation Overall First Place Oral Presentation 2000
- American Association of Cancer Research Scholar-in-Training Award 2004
- West Virginia University School of Medicine Van Lier Research Convocation Second Place Poster Presentation 2005
- Association of Residents in Radiation Oncology Poster Walk Selection at American Society for Radiation Oncology Annual Meeting 2009
- Association of Residents in Radiation Oncology Poster Walk Selection at American Society for Radiation Oncology Annual Meeting 2010
- The University of Texas MD Anderson Cancer Center Trainee Research Day Award Finalist 2010
- American Society for Radiation Oncology Travel Award and Plenary Session Honors 2010
- Radiological Society of North America Roentgen Resident/Fellow Research Award 2011
- The University of Texas MD Anderson Cancer Center Trainee of the Quarter 2011
- American Society of Clinical Oncology Merit Award 2012
- The University of Texas MD Anderson Cancer Center Lupe C. Garcia Fellowship in Cancer Research 2012
- The University of Texas MD Anderson Cancer Center Thomas H. and Mayme P. Scott Fellowship in Cancer Research 2012
- American Society for Radiation Oncology Fundamentals of Leadership Training 2012
- UPMC Hillman Cancer Center Hillman Fellow for Innovative Cancer Research 2019
- Elected Member of the American Society for Clinical Investigation 2020
- UPMC – Excellence in Patient Experience, Top Physician by Specialty 2022

PROFESSIONAL ACTIVITIESCLINICAL SERVICES:

2012 – present	Thoracic Radiation Oncology
2012 – present	Head and Neck Radiation Oncology
2012 – present	Stereotactic Body Radiotherapy
2012 – present	Palliative Radiation Oncology

CLINICAL TRIALS:

- Principal Investigator, ECOG 3222 Phase II Trial of Xevinapant and Chemoradiotherapy in Adjuvant Treatment for Patients with Head and Neck Squamous Cell Carcinoma with High-Risk Pathologic Features”, CTEP- approved, awaiting activation
- Principal Investigator, TRILOC (HCC 22-030), ongoing, Investigator initiated trial.
- Principal Investigator, Radiotherapy with Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (HCC 13-056), ongoing, Investigator initiated trial.
- Site principal investigator HN-005 (HCC 20-131): A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer, ongoing
- Site principal investigator, HCC 20-082: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
- Principal Investigator, Metformin in Non-Small Cell Lung Cancer (NSCLC), NCT02285855, NIH/Investigator-initiated trial, completed
- Principal Investigator, NRG-LU001 A Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC, NRG-LU001, NIH/NRG, completed
- Principal Investigator, 4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients with Thoracic Malignancies, completed

JOURNAL REVIEW:

- | | |
|--|----------------|
| • Reviewer, Cancer | 2010 – present |
| • Reviewer, The Journal of Hepatology | 2010 – present |
| • Reviewer, Head and Neck | 2011 – present |
| • Reviewer, Radiation Oncology | 2011 – present |
| • Reviewer, Infectious Agents and Cancer | 2012 – present |
| • Reviewer, PLOS One | 2013 – present |
| • Reviewer, The Oncologist, AlphaMed Press | 2013 – present |
| • Reviewer, Clinical Cancer Research | 2015 – present |
| • Reviewer, Journal of the National Cancer Institute | 2015 – present |
| • Reviewer, Molecular Cancer Therapeutics | 2017 – present |
| • Reviewer, Cancer Research | 2018 – present |
| • Reviewer, Scientific Reports | 2019 – present |
| • Reviewer, Nature Communications | 2020 – present |
| • Reviewer, Journal of Clinical Investigation | 2020 – present |
| • Reviewer, The FASEB Journal | 2023 – present |

JOURNAL EDITOR:

- Academic Editor, *PLOS One* 2018 – 2022

GRANT REVIEW:

- Reviewer, Irish Health Research Board 2016
- Reviewer, KWF Kankerbestrijding (Dutch Cancer Society) 2015
- Reviewer, Brandon C. Gromada Head & Neck Cancer Foundation 2015
- Reviewer, National Cancer Institute SPORE Review Panel September 26 – 27, 2019
- Reviewer, National Cancer Institute, Cancer Biotherapeutics Development Study Section November 12 – 13, 2020; March 18 – 19, 2021
- Reviewer, National Institute of Dental and Craniofacial Research, Special Emphasis Panel, June 24, 2021
- Reviewer, National Cancer Institute Special Emphasis Panel, October 12 – 13, 2021
- Reviewer, National Cancer Institute, Special Emphasis Panel (ROBIN) February 3 – 4, 2022
- Programmatic Reviewer (*Ad hoc*), Department of Defense, Peer-reviewed Cancer Research Program December 8 – 9, 2021
- Programmatic Reviewer (*Ad hoc*), Department of Defense, Peer-reviewed Cancer Research Program February 2, 2022
- Programmatic Reviewer, Full member, Department of Defense, Peer-reviewed Cancer Research Program November, 2022-present

CURRENT RESEARCH INTERESTS:

Dr. Skinner's laboratory and clinical efforts are mainly focused upon identifying novel, targetable biomarkers of resistance to radiation treatment in upper-aerodigestive tract malignancies. His group utilizes pre-clinical screening models as well as “-omic” analysis of patient tumors to identify potential drivers of radioresistance. These drivers are then studied to provide insight into the underlying radiobiology and serve as targets for novel therapeutics in clinical trials led by his group and others.

INVITED SEMINARS AND LECTURESHIPS:

CONFERENCE ORGANIZER:

- Advances in Cancer Immunotherapy, Society for Immunotherapy of Cancer, Pittsburgh, PA 2020
- UPMC Hillman Head and Neck Cancer Symposium, Pittsburgh, PA 2021
- 9th Annual International UPMC Radiotherapy Symposium, Rome, Italy 2022

INTERNATIONAL PRESENTATIONS

- Personalized external beam radiotherapy, 26th Annual Meeting of Japan 3-D Conformal External Beam Radiotherapy Group, Kyoto, Japan 2013

- Identifying targetable markers of radioresistance, International Summit on Biomarkers and Therapeutic Advances in Radiation Oncology, McGill University Health Center, Montreal, Quebec, Canada 2016
- Using neoadjuvant trials to drive progress in H&N cancer immunotherapy, Immunotherapy/Melanoma Bridge, Naples, Italy 2019
- Interaction and Synergies between New Drugs and SBRT in Treating Lung Cancer, 7th International UPMC Radiotherapy Symposium, Rome, Italy 2019
- New Radiotherapy Techniques and Clinical Protocols, 9th Annual International UPMC Radiotherapy Symposium, Rome, Italy 2022
- Multidisciplinary management of challenging skull base tumors, IFHNOS, Rome, Italy 2023
- Targetable drivers of radioresistance in head and neck cancer: challenges and opportunities, IFHNOS, Rome, Italy 2023
- Machine learning to identify biomarkers of response and outcome in HNSCC, IFHNOS, Rome, Italy 2023
- Recent Clinical Trials for Locally Advanced Nasopharyngeal Cancer, AHNS Annual Conference, Montreal, Canada 2023
- Adaptive replanning based on CT images, 10th Annual Rome Symposium, Rome, Italy 2023
- Modern Radiotherapy Approaches of HNSCC, Interdisciplinary Tumor Board and Case Discussions; Tumor Board – Skull Base Malignancies, Tumor Board and Case Discussions, 95th Annual Meeting of the German Society of ORL-HNS 2024, Essen, Germany 2024
- 12th Annual Rome Symposium, Rome, Italy 2025

NATIONAL PRESENTATIONS

- Outcome of malignant tumors of the lacrimal apparatus: The MD Anderson experience, 2nd Annual ASTRO Multidisciplinary Head and Neck Cancer Symposium, Chandler, AZ 2010
- Metformin use is associated with improved response to neoadjuvant chemoradiation in esophageal adenocarcinoma, 54th Annual Meeting of the American Society of Radiation Oncology, Boston, MA 2012
- Advice for MD/PhD students and current research, West Virginia University, Morgantown, WV 2011
- Personalized therapy in Head and Neck Cancer, West Virginia University, Morgantown, WV 2012
- Metformin as a potential radiosensitizer in lung cancer, NRG Oncology, San Diego CA 2013
- The development of novel biomarkers of radiosensitivity in head and neck cancer, NRG Oncology, San Diego, CA 2015
- Identifying Novel targets for radiosensitization., University of North Texas Health Science Center, Fort Worth, TX 2015

- Identifying targetable biomarkers of failure following radiation, NRG Oncology, Houston, TX 2017
- The use of metformin as radiosensitizer in rectal cancer, NRG Oncology, Houston, TX 2017
- Identifying Novel Targets for Radiosensitization in Head and Neck Cancer, The Ohio State University, Columbus, OH 2017
- *In vivo* shRNA screening identifies synthetic cytotoxicity in CREBBP/EP300 mutant head and neck cancer, AACR Annual Meeting 2018, Chicago, IL 2018
- SBRT and lung toxicity abstract discussant, ASTRO Annual Meeting, San Antonio, TX 2018
- HPV Associated Cancers and Radiation Response, Radiation Research Society Annual Meeting, San Diego, CA 2019
- *In vivo* shRNA screening identifies synthetic cytotoxicity in CREBBP/EP300 mutated tumors in head and neck cancer, Ohio State University, Columbus, OH 2019
- Identifying novel targets for radiosensitization in head and neck cancer, Radiation Oncology Grand Rounds and Visiting Professor, Memorial Sloan Kettering Cancer Center, New York, NY 2020
- Instructional Course 11: Genetic Drivers of Resistance, American Head and Neck Society (AHNS), 10th International Conference on Head and Neck Cancer (Delayed until 2021 due to COVID-19) 2020
- Instructional Course 34: Intersection of Radiation and Immunotherapy, American Head and Neck Society (AHNS), 10th International Conference on Head and Neck Cancer 2020
- Identifying novel biomarkers of outcome following radiation in head and neck cancer, 3rd Annual Head and Neck Cancer Conference, UCSD San Diego, CA (Delayed until 2021 due to COVID-19) 2020
- Discussant Head and Neck Quick Pitch Session, ASTRO Annual Meeting (Held virtually due to COVID-19) 2020
- Moderator, American Head and Neck Society International Conference on Head and Neck Cancer (Held virtually due to COVID-19) 2021
- Chair and presenter, Education Session “Integration of Surgery in the Multidisciplinary Care of Head and Neck Cancer: Focus on Oral Cavity, Larynx, and Hypopharynx Cancers” ASTRO Annual Meeting, Chicago, IL 2021
- Novel roles for p16 in head and neck cancer, Grand Rounds, Baylor College of Medicine (Held virtually due to COVID-19) 2022
- Novel Radiosensitizers, ASTRO-ASCO-AHNS Multidisciplinary Head and Neck Symposium, Phoenix AZ 2022
- Moderator, American College of Radiation Oncology Annual Summit, Fort Lauderdale, FL 2022
- Chair and Speaker, Multidisciplinary Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Educational Session, ASTRO Annual Meeting, San Antonio, TX 2022

- Thinking Beyond PD-1 for Radiation Combinatorial Therapy, Multidisciplinary Head and Neck Cancer Conference and 5th New Horizons in Immunotherapy Conference, San Diego, CA 2022
- Head and Neck Poster Session: Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer, ASCO Annual Meeting, Chicago, IL 2023
- Non-Canonical Roles for p16 in Head and Neck Cancer, Radiation Oncology Grand Rounds, Yale University School of Medicine 2023
- HATs and Response to DNA-Targeted Therapy, Cancer Center Grand Rounds, Winship Cancer Center, Emory University 2024
- Speaker - What is Next Following Induction Chemotherapy for SCC and SNUC? Considerations in Radiotherapy – When to Choose Between Definitive, Post OP, Preop Radiotherapy; NASBS/WFSBS Joint Meeting, New Orleans, LA 2025
- Speaker/Panelist – Emerging Treatments and Diagnosis of Head and Neck Cancers; De-Escalation of Surgery, Radiation and Systemic Treatment; Henry Ford Cancer Institute – Head and Neck Cancer Symposium. Detroit, MI 2025

REGIONAL PRESENTATIONS:

- Identifying and targeting biomarkers of radioresistance in head and neck cancer, Texas Screening Alliance for Cancer Therapeutics, Houston, TX 2015
- Metformin as a Therapeutic Adjunct in Solid Tumors, University of Pittsburgh Hillman Cancer Center Aging and Cancer Symposium 2019
- Advances in Radiotherapies: Therapeutic Outcomes in Head and Neck Cancer, Survivorship after Cancer of the Head and Neck: A Multidisciplinary Symposium, Pittsburgh, PA 2019
- Moderator, Panel Discussion: Management of the Cascade of Symptoms After Therapy, Survivorship after Cancer of the Head and Neck: A Multidisciplinary Symposium, Pittsburgh, PA 2019
- New Horizons for Radiation in the Management of Smoking-Related Cancer, West Virginia University 29th Annual Fall Cancer Conference 2019
- Journal Club: H&N: Post-Op/Oral Cavity/Unusual with Dr. Skinner 2022
- Case Discussion with Dr. Skinner: Postop oral cavity and include PNI cases for different Cranial Nerves 2022
- Robotic Surgery Conference – Virtual Conference – Innovations in Radiation Therapy for Head & Neck Cancer 2025
- Panel Member - Breakout Q&A Session on Trainee Career Development – UPMC Hillman Annual Scientific Retreat, Pittsburgh, PA 2025
- Department of Epidemiology 2025 Fall Seminar Series Area of Emphasis: Cancer – Thinking Past PD-1 in Head and Neck Cancer; University of Pittsburgh, Pittsburgh, PA 2025

UNIVERSITY AND PUBLIC SERVICE

NATIONAL SERVICE:

- NRG Oncology Lung Committee, Member and PI 2013 – present
- ASTRO Thoracic Section, Abstract Reviewer 2013 – 2019
- ASTRO Oral presentation moderator, Thoracic Section 2013
- ASTRO Biology Section, Abstract Reviewer 2014 – 2019
- ARS Thoracic Section Oral Presentation, Moderator 2017
- ARS Oral presentation Biology Section, Moderator 2018
- NCI Head and Neck Steering Committee's Previously Untreated Locally Advanced (PULA) Task Force, Member 2018 – present
- ASTRO Oral presentation Moderator 2019
- ASTRO "Meet the Expert," Head and Neck Session 2019
- NIDCR Data and Safety Monitoring Board (DSMB), Member 2019 – present
UW Head and Neck SPORE, Designated Data Safety Monitoring Officer
- ASTRO Abstract reviewer, Head and Neck Section 2019 – present
- ASTRO Education Committee 2019 – present
- HNSC TP53 Mutated Head & Neck Cancer Clinical Trials Planning Meeting Locally Advanced Group, Co-Chair 2020
- American Board of Radiology, Radiation Oncology Head, Neck and Skin Certification Exam Committee, Member 2020 – present
- ECOG-ACRIN Head and Neck Committee, Member 2020 – present
- ASTRO Education Committee, chair Thoracic Track 2022 – present
- NCI Head and Neck Steering Committee 2023 – present
- NIH Review Panel on Cancer Nanomedicine - Chair 2024 – present

UNIVERSITY AND MEDICAL SCHOOL SERVICE:

- MDACC Radiation Oncology Quality and Safety Committee, Member 2009 – 2011
- MDACC Radiation Oncology Anderson Award 2010 Committee, Member 2010
- MDACC Radiation Oncology Physics Curriculum Committee, Member 2011 – 2014
- MDACC AACR Translational Research Fellowship Committee, Member 2012 – 2013
- MDACC Odyssey Program Advisory Committee, Member 2012 – 2015
- MDACC Odyssey Program Advisory Committee, Co-Chair 2013 – 2014
- MDACC Odyssey Program Advisory Committee, Chair 2014 – 2015
- MDACC Vendor Selection and Contracts Committee, Member 2014 – 2015
- MDACC Molecular Testing and Evaluation Committee, Member 2014 – 2016
- MDACC Medical Practice Committee, Member 2014 – 2018

- UPMC Hillman Cancer Center Research Executive Advisory Committee (REAC), Member 2018 – present
- Department of Radiation Oncology Medical Management Committee, Member 2020 – 2022
- Radiation Oncology Modality Center, Director 2020 – present
- Head and Neck Center Basic and Translational Research, Director 2020 – present
- Urology Chair Search Committee member 2023 – present
- Hillman Cancer Center Director Search Committee member 2024 – present
- University of Pittsburgh Chair of Radiology Search Committee member 2025 - present

TEACHING AND MENTORING

TEACHING:

- Teaching Assistant, Microbiology Laboratory, West Virginia University, Course Hours: 3, 2nd Year WVU Medical Students, 8/2003 – 12/2003
- Lecturer, Advanced pathophysiology, MD Anderson Cancer Center, Course Hours: 15, 7/2009 – 2/2012
- Lecturer, MD Anderson Cancer Center, Medical dosimetry program, Course Hours: 3, 5/2011 – 6/2011
- Course coordinator and Lecturer, Short course in radiobiology for radiation oncology residents, Course Hours: 8 hours, 2/2012-2/2016
- WVU School of Medicine invited Cancer Cell Biology lecture for graduate students – 10/16/2020
- Re-irradiation in HNC, University of Pittsburgh ENT Resident Journal Club, 10/22/2020
- All Things OPX, UPMC Hillman Cancer Center Radiation Oncology Resident Lecture, 2020, 2022, 2023
- Lecturer, H&N Clinical Discussion (Libya Course) for AAPM – 2024

TRAINEE EDUCATION AND MENTORSHIP:

THORACIC RADIATION ONCOLOGY FOR RESIDENTS:

2012-2017: 3-4 trainees per one-hour lecture, 8 hours/year

CLINICAL INSTRUCTION AND MENTORSHIP TO THE FOLLOWING TRAINEES:

5/2013 – 6/2013: Mark Edson, Radiation Oncology Resident (MDACC)

10/2013 – 12/2013: Chad Tang, Radiation Oncology Resident (MDACC)

6/2014 – 8/2014: Wen Jiang, Radiation Oncology Resident (MDACC)

8/2014 – 10/2014: Brian Deegan, Radiation Oncology Resident (MDACC)

8/2014 – 10/2014: Aaron Grossberg, Radiation Oncology Resident (MDACC)

10/2014 – 12/2014: Sean Quinlan – Davidson, Radiation Oncology Fellow (MADCC)

3/2015 – 5/2015: Jennifer Ho, Radiation Oncology Resident (MDACC)

5/2015 – 6/2015: Hubert Pan, Radiation Oncology Resident (MDACC)

7/2015 – 8/2015: Andrew Bishop, Radiation Oncology Resident (MDACC)

8/2015 – 11/2015: Jennifer Logan, Radiation Oncology Resident (MDACC)

2/2016 – 5/2016: Randa Tao: Radiation Oncology Resident (MDACC)

2/2016 – 5/2016: Jennifer Logan, Radiation Oncology Resident (MDACC)

9/2016 – 11/2016: Penny Fang, Radiation Oncology Resident (MDACC)

1/2017 – 3/2017: Ethan Ludmir, Radiation Oncology Resident (MDACC)

3/2017 – 5/2017: Shalini Moningi, Radiation Oncology Resident (MDACC)

5/2017 – 7/2017: Ahsan Farooqi, Radiation Oncology Resident (MDACC)

5/2017 – 7/2017: Chris Wilke, Radiation Oncology Fellow (MDACC)

7/2017 – 9/2017: Mark Armsbaugh, Radiation Oncology Fellow (MDACC)

9/2017 – 11/2017: Dario Pasalic, Radiation Oncology Resident (MDACC)

9/2017 – 11/2017: Eric Brooks, Radiation Oncology Resident (MDACC)

3/2018 – 5/2018, Dario Pasalic, Radiation Oncology Resident (MDACC)

5/2018 – 7/2018, Alexander Augustyn, Radiation Oncology Resident (MDACC)

5/2019, Joshua Rodriguez-Lopez, Radiation Oncology Resident (UPMC/U. Pitt)

6/2020– 2/2021: Phillip Pifer, Radiation Oncology Resident (UPMC/U. Pitt)

7/2020 – 9/2020: Hima Musunuru, Radiation Oncology Resident (UPMC/U. Pitt)

3/2021 – 5/2021: Adam Richman, Radiation Oncology Resident (UPMC/U. Pitt)

5/2021 – 7/2021: Joshua Rodriguez, Radiation Oncology Resident (UPMC/U. Pitt)

9/2021 – 11/2021: Andrew Keller, Radiation Oncology Resident (UPMC/U. Pitt)

4/2022 – 6/2022: Mohamed Abdelhakiem, Radiation Oncology Resident (UPMC/U. Pitt)

9/2022 – 11/2022: Phillip Pifer, Radiation Oncology Resident (UPMC/U. Pitt)

11/2022 – present: Mohammed Mohammed, Radiation Oncology Resident (UPMC/U. Pitt)

2/2023 – present: Diala Hamade, Radiation Oncology Resident (UPMC/U. Pitt)

7/2023 – 6/2025: Baher Elgohari, Radiation Oncology Resident (UPMC/U. Pitt)

9/2023 – 6/2025: Ria Mulherkar, Radiation Oncology Resident (UPMC/U. Pitt)

11/2023 – 2/2024: Sean Koerner, Radiation Oncology Resident (UPMC/U. Pitt)

2023 – present: Jeffrey Shogan, Radiation Oncology Resident (UPMC/U. Pitt)

2023 – present: Alberto Vera, Radiation Oncology Resident (UPMC/U. Pitt)

2024 – present: Muhammad Shohayeb, Radiation Oncology Resident (UPMC/U. Pitt)

2024 – present: Edmond Yaghoubian, Radiation Oncology Resident (UPMC/U. Pitt)

2025 – present: Abigail Groszkiewicz, Radiation Oncology Resident (UPMC/U. Pitt)

2025 – present: Reeny Thomas, Radiation Oncology Resident (UPMC/U. Pitt)

- Biannual formal one-on-one mentoring meetings with all trainees.
- Monthly Translational Radiation Oncology Research Meetings with residents and faculty
- Monthly Research Check-ins with residents

UNIVERSITY OF PITTSBURGH MEDICAL SCHOOL COURSE (MED 5715, NEOPLASIA AND NEOPLASTIC DISEASE) LECTURE:

3/7/2019: *Radiation Therapy Management (Lung Cancer)*

UPMC HEMATOLOGY/ONCOLOGY FELLOWSHIP DIDACTIC SESSION:

4/5/2019 and 8/21/2020: *Radiation Oncology for the Non-radiation Oncologist*

UPMC RADIATION ONCOLOGY DIDACTIC SESSION:

8/2/2019, 8/4/2020: *All things oropharynx*

RESEARCH INSTRUCTION AND MENTORSHIP TO THE FOLLOWING TRAINEES:

11/2013 – 5/2014: Sarah McAvoy MD, Radiation Oncology Resident

- McAvoy SA, Soh HE, Komaki R, Cox JD, Welsh JW, Guerrero TM, **Skinner HD**. Metformin Use Does Not Affect Chemoradiotherapy – Associated Toxicity. *Oncology*. 2014;28(1S)

1/2013 – 4/2014: Hui – Ching (Julia) Chuang MD, Head and Neck Surgical Fellow

- Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, **Skinner HD**. The p53 – Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells. *PLoS One* 9(8):e104821, 2014. e – Pub 8/2014. PMCID: PMC4132078.
- Dr. Chuang was promoted to Chairperson of the Department of Otolaryngology, Kaosiung Chang Gung Memorial Hospital in 2021.

1/2013 – 6/2015: Sang Hyeok Woo PhD, Visiting Post – Doctoral Fellow (Home institution: Seoul National University, Seoul 151 – 742, Republic of Korea) (4 total publications)

- Woo SH, Yang LP, Chuang HC, Fitzgerald A, Lee HY, Pickering C, Myers JN, **Skinner HD**. Down – regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy – induced senescence. *Head Neck* 38 Suppl 1:E934 – 940, 4/2016. e – Pub 7/2015. PMID: 25994759.

- Woo SH, Sandulache VC, Yang L, **Skinner HD**. Evaluating Response to Metformin/Cisplatin Combination in Cancer Cells via Metabolic Measurement and Clonogenic Survival. *Methods Mol Biol* 1165:11 – 18, 2014. PMID: 24839015.

3/2016 – 3/2017: Xiyu Liu PhD, Visting Graduate Student (Home institution: Huazhong University of Science and Technology, Tongji Medical College, Tongji Hospital)

- Liu X*, Kumar M*, Yang L, Molkentine DP, Valdacas D, Yu S, Meyn RE, Heymach J, **Skinner HD**. BAP1 is a novel target in HPV negative head and neck cancer. *Clin Cancer Res* 24(3), 2/2018. PMID: 29113987. (*contributed equally)

3/2016 – 8/2018: Manish Kumar PhD, Post – doctoral fellow (2 publications and one in preparation)

- Liu X*, Kumar M*, Yang L, Molkentine DP, Valdacas D, Yu S, Meyn RE, Heymach J, **Skinner HD**. BAP1 is a novel target in HPV negative head and neck cancer. *Clin Cancer Res* 24(3), 2/2018. PMID: 29113987. (*contributed equally)
- Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, **Skinner HD**. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. *Nat Commun*. 2021 Nov 3;12(1):6340. PMID: 34732714.

6/2017 – 5/2018: Aakash Sheth BS, Medical Student

- Oral presentation: 2018 – In Vivo Screening Identifies ESR1 as a Clinically Relevant Target for Radiosensitization in HNSCC, ARS Annual Meeting, Orlando, FL

10/2017 – 9/2018: Lauren Colbert MD PhD, Radiation Oncology Resident

- Oral presentation: 2018 – In Vivo shRNA Screening Reveals Differential Radiosensitization Within HPV+ and HPV – Head and Neck Squamous Cell Carcinomas, ASTRO Annual Meeting, San Antonio, TX

10/2019 – 2023: Mohamed Abdelhakiem MD, Post – doctoral fellow and Radiation Oncology Resident

- Poster presentation: 2020 – Association of radiation treatment failure in head and neck cancer with differential immune infiltrate. ASCO Annual Meeting (virtual due to COVID – 19)
- Oral presentation: 2020 – Mutations in CASP8 and the Histone Acetyltransferases CREBBP and EP300 are Associated with Treatment Failure in Head and Neck Squamous Cell Carcinoma. ASTRO Annual Meeting (virtual due to COVID – 19)
- Abdelhakiem M, Bao R, Pifer PM, Molkentine D, Molkentine J, Hefner A, Beadle BM, Heymach J, Luke JJ, Ferris RL, Pickering C, Wang JH, Patel RB, **Skinner HD**. Th2 cells are associated with tumor recurrence following radiation. [Internet]. In Review; 2022 Apr. Available from: <https://www.researchsquare.com/article/rs-1537302/v2>. PREPRINT

10/2020 – 2023: Phillip Pifer MD, PhD, Post – doctoral fellow, and Radiation Oncology Resident

- Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, Beadle B, Molkentine D, Molkentine J, Dhawan A, Abdelhakiem M, Osman AA, Leibowitz BJ, Myers JN, Pickering CR, Sandulache VC, Heymach J, **Skinner HD**. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 Jan 5;30(1):187-197. doi: 10.1158/1078-0432.CCR-23-0964. PMID: 37819945; PMCID: PMC10767302.
- Dhawan A, Pifer PM, Sandulache VC, **Skinner HD**. Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here? Front Oncol. 2022 Dec 14;12:1016217. doi: 10.3389/fonc.2022.1016217. PMID: 36591457; PMCID: PMC9794617.
- American Society of Clinical Oncology Young Investigators Award, “B7 – H3 in head and neck squamous cell carcinoma,” awarded 7/2/2022

7/2022 – 2022: Hima Musunuru MD, Radiation Oncology Resident

SBRT for early-stage NSCLC: Is it essential to target the unseen disease?

Hima Bindu Musunuru, **Heath Skinner**, Tyler Wilhite. September 2022. ASCO Daily News

RESEARCH INSTRUCTION AND MENTORSHIP FOR THE FOLLOWING FACULTY:

7/2020 – present: Uzoma Iheagwara MD, PhD, Assistant Professor of Radiation Oncology

- Head and Neck SPORE Career Development Award in 2020.
- EMD Serono “I’m IN” Fellowship Award to improve Oncodisparity in Head and Neck Cancer

7/2019 – present: Adam Olson, MD, Assistant Professor of Radiation Oncology

- Mentorship submitting multi-PI R01 studying SBRT for ventricular arrhythmia and ASTRO Career Development Award as well as in clinical trial design.

6/2020 – present: Ravi Patel, MD, PhD, Assistant Professor of Radiation Oncology

- Multi-PI R01 and DOD IMPACT award submissions, weekly research and career development meetings.
- Head and Neck SPORE Career Enhancement Award in 2023.

3/2021 – present: Parul Barry, MD, Assistant Professor or Radiation Oncology

- Approximately monthly grant and clinical trial development meetings, culminating in a clinical trial concept moving forward internally: “Preoperative Irradiation for Stage I Breast Cancer: A Phase IB Study”

6/2023 – present: Brian Leibowitz, PhD

- Mentored to first RO1 submission as MPI, “Targeting Focal Adhesion Kinase in TP53 mutant head and neck cancer.”
- Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, Beadle B, Molkentine D, Molkentine J, Dhawan A, Abdelhakiem M, Osman AA, Leibowitz BJ, Myers JN, Pickering CR, Sandulache VC, Heymach J, **Skinner HD**. FAK Drives Resistance to Therapy in HPV-

Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 Jan 5;30(1):187-197. doi: 10.1158/1078-0432.CCR-23-0964. PMID: 37819945; PMCID: PMC10767302.

7/2023 – present: Yvonne Mowery, MD, PhD, DABR

10/2023 – present: Angela Mazul, PhD

- EMD Serono “I’m IN” Fellowship Award to improve Oncodisparity in Head and Neck Cancer
- CURRICULUM DEVELOPMENT/TEACHING PRODUCTS/MEDIA PRODUCTS:

8/2014 – 8/2015: ASCO Radiation Oncology Primer, ASCO University, Course Hours: 1, This course is an overview of Radiation Oncology for colleagues in other medical specialties. Along with two additional colleagues, I designed and gave the content of this CME course.

5/2023: Using Radiation to Treat Cancer, Course Hours: 0.75. An overview of radiation oncology geared toward physicians in other fields. I designed and gave the content for this course.

<https://www.upmcphysicianresources.com/cme-courses/using-radiation-to-treat-cancer>

- Developed UPMC Network-wide prospective SBRT chart review

1/2024 – present: Charles T. Mupamombe MD, HMDC, FACP

4/2024 – present: Susannah Ellsworth, MD

6/2024 – present: Hayeon Kim, PhD, DABR

2024- present: Adam Mueller, MD, PhD

2024- present: Bhanu Venkatesulu, MBBS, MD

4/2025 – present: Marko Bebek, MD – Medical Director, Croatia

11/2025 – present: Jessie Nedrow, Assistant Professor Radiology

PUBLICATIONS

PEER REVIEWED REFEREED ARTICLES:

1. Griffin WC 3rd, **Skinner HD**, Salm AK, Birkle DL. Mild prenatal stress in rats is associated with enhanced conditioned fear. *Physiol Behav* 79(2):209 – 215, 2003.
2. **Skinner HD**, Zhong XS, Gao N, Jiang BH. Arsenite induces p70S6K1 activation and HIF – 1 α levels in prostate cancer cells. *Mol Cell Biochem* 255(1 – 2):19 – 23, 2004.
3. Somasudar P, Krankenberg K, **Skinner HD**, Vedula G, McFadden D, Riggs D, Jackson B, Vangilder R, Hileman S, Vona – Davis L. Prostate cancer cell proliferation is influenced by leptin. *J Surg Res* 1(118):71 – 82, 2004.
4. **Skinner HD**, Zheng J, Gao N, Agani F, Jiang BH. VEGF transcriptional activity via HIF – 1 α expression is dependent upon P13K – mediated activation of p70S6K and hdm2 in ovarian cancer. *J Biol Chem* 279(44):45643 – 45651, 2004.
5. Griffin WC 3rd **Skinner HD**, Birkle DL. Prenatal stress influences 8 – OH – DPAT modulated startle responding and [(3)] – 8 – OH – DPAT binding in rats. *Pharmacol Biochem Behav* 81(3):601 – 607, 2005.

6. Frankenberry K, **Skinner HD**, Somasundar P, McFadden D, Vona – Davis L. Leptin receptor expression and cell signaling in breast cancer. *Int J Oncol* 28(4):985 – 993, 2006.
7. Zhong XS, Liu LZ, **Skinner HD**, Cao Z, Ding M, Jiang BH. Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells. *Biochem Biophys Res Commun* 358(1):92 – 98, 2007.
8. Jiang Y, Cukic B, Adjero DA, **Skinner HD**, Lin J, Shen QJ, Jiang BH. An algorithm for identifying novel targets of transcription factor families: application to hypoxia – inducible factor 1 targets. *Cancer Inform* 7:75 – 89, 2009.
9. **Skinner HD**, Garden AS, Rosenthal DI, Ang KK, Morrison WH, Esmaili B, Pinnix CC, Frank SJ. Outcomes of malignant tumors of the lacrimal apparatus: The University of Texas MD Anderson Cancer Center Experience. *Cancer* 117(12):2801 – 2010, 2011.
10. **Skinner HD**, Sharp HJ, Kaseb AO, Javle MN, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. *Acta Oncol* 50(8):1191 – 1198, 2011.
11. **Skinner HD**, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation – induced senescence. *Clin Cancer Res* 18(1):290 – 300, 1/2012. e – Pub 11/2011. PMCID: PMC3251726.
12. Sandulache VC, **Skinner HD**, Wang Y, Chen Y, Dodge CT, Ow TJ, Bankson JA, Myers JN, Lai SY. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. *Mol Cancer Ther* 11(6):1373 – 1380, 6/2012. e – Pub 5/2012. PMID: 22572813.
13. Sandulache VC, **Skinner HD**, Ow TJ, Zhang A, Xia X, Luchak JM, Wong LC, Pickering CR, Zhou G, Myers JN. Individualizing anti – metabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. *Cancer* 118(3):711 – 712, 2012.
14. **Skinner HD**, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, Booser DJ, Meric – Bernstam F, Buchholz TA. Radiation dose escalation for loco – regional recurrence of breast cancer after mastectomy. *Radiat Oncol* 8:13, 1 – 9, 1/2013. e – Pub 1/2013. PMCID: PMC3552737.
15. **Skinner HD**, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez – Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das P. Metformin use and improved response to therapy in rectal cancer. *Cancer Med* 2(1):99 – 107, 2/2013. e – Pub 2/2013. PMCID: PMC3797563.
16. **Skinner HD**, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. *Acta Oncol* 52(5):1002 – 1009, 6/2013. e – Pub 9/2012. PMID: 22950385.
17. Hamilton JD, Ahmed S, Sandulache VC, Daram SP, Ow TJ, **Skinner HD**, Rao A, Ginsberg LE, Kumar AJ, Myers JN. Improving imaging diagnosis of persistent nodal metastases after definitive therapy for oropharyngeal carcinoma: specific signs for CT and best performance of combined criteria. *AJNR Am J Neuroradiol* 34(8):1637 – 1642, 8/2013. e – Pub 3/2013. PMCID: PMC3939678.

18. Sandulache VC, Kubik MW, **Skinner HD**, Malsky JA, Gelbard AH, Zevallos JP. Impact of race/ethnicity on laryngeal cancer in patients treated at a Veterans Affairs Medical Center. *Laryngoscope* 123(9):2170 – 2175, 9/2013. e – Pub 5/2013. PMID: 23729204.
19. Sandulache VC, Ow TJ, Daram SP, Hamilton J, **Skinner HD**, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El – Naggat AK, Myers JN. Residual nodal disease in patients with advanced – stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. *Head Neck* 35(10):1454 – 1460, 10/2013. e – Pub 9/2012. PMID: 23018868.
20. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, **Skinner HD**, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. *Ann Oncol*, 11/2013.
21. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, **Skinner HD**, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies. *J Clin Oncol* 31(34):4306 – 4310, 12/2013. e – Pub 10/2013. PMCID: PMC3837091.
22. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, **Skinner HD**, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. *Oncology* 85(4):204 – 207, 2013. e – Pub 9/2013. PMID: 24051869.
23. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, **Skinner HD**, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity – based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. *Oncology* 85(2):95 – 99, 2013. e – Pub 7/2013. PMID: 23860252.
24. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, **Skinner HD**, Johnson RL, Berry D. ALDH – 1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. *Mol Oncol* 8(1):142 – 149, 2/2014. e – Pub 10/2013. PMCID: PMC3946849.
25. Hoffman KE, Voong KR, Pugh TJ, **Skinner H**, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose – escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. *Int J Radiat Oncol Biol Phys* 88(5):1074 – 1084, 4/2014. PMID: 24661661.
26. **Skinner HD**, Sturgis EM, Klopp AH, Ang KK, Rosenthal DI, Garden AS, Morrison WH, Gunn GB, Beadle BM. Clinical characteristics of patients with multiple potentially human papillomavirus – related malignancies. *Head Neck* 36(6):819 – 825, 6/2014. e – Pub 9/2013. PMID: 23720126.
27. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, **Skinner HD**, Fitzgerald AL, Osman AA, Wei Y, Xia X, Songyang Z, Mills GB, Hung MC, Caulin C, Liang J, Myers JN. Gain – of – Function Mutant p53 Promotes Cell

- Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. *Mol Cell* 54(6):960 – 974, 6/2014. e – Pub 5/2014. PMCID: PMC4067806.
28. Sandulache VC, Hamblin JS, **Skinner HD**, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. *Head and Neck* 36(7):1039 – 1043, 7/2014.
 29. Honjo S, Ajani JA, Scott AW, Chen Q, **Skinner HD**, Strohlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. *Int J Oncol* 45(2):567 – 574, 8/2014. e – Pub 5/2014. PMCID: PMC4091970.
 30. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, **Skinner HD**, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post – chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. *J Natl Compr Canc Netw* 12(8):1139 – 1144, 8/2014. PMID: 25099446.
 31. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, **Skinner HD**, Ajani JA. Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer. *J Clin Oncol* 32(30):3400 – 3405, 10/2014. e – Pub 9/2014. PMCID: PMC4195852.
 32. Raju U, Molkentine DP, Valdecanas DR, Deorukhkar A, Mason KA, Buchholz TA, Meyn RE, Ang KK, **Skinner HD**. Inhibition of EGFR or IGF – 1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit. *Cancer Med.* 4(1):65 – 74, 1/2015. e – Pub 10/2014. PMID: 25355701.
 33. Wen CP, Zhang F, Liang D, Wen C, Gu J, **Skinner HD**, Chow WH, Ye Y, Pu X, Hildebrandt MA, Huang M, Chen CH, Hsiung CA, Tsai MK, Tsao CK, Lippman SM, Wu X. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. *Clin Cancer Res.* 1;21(1):193 – 200, 1/2015. e – Pub 10/2014. PMID: 25336700.
 34. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, **Skinner HD**, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation – related genetic variants predict toxicity following definitive radiotherapy for lung cancer. *Clin Pharmacol Ther* 96(5):609 – 615, 11/2014. e – Pub 7/2014. PMCID: PMC4206576.
 35. **Skinner HD**, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. *Cancer* 120(23):3635 – 3641, 12/2014. e – Pub 8/2014. PMCID: PMC4239178.
 36. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, **Skinner HD**, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and Timing of Distant Metastasis after Local Therapy in a Large Cohort of Patients with Esophageal and Esophagogastric Junction Cancer. *Oncology* 86(5 – 6):336 – 339, 2014. e – Pub 6/2014. PMCID: PMC4105702.
 37. Sandulache VC, Chen Y, Lee J, Rubinstein A, Ramirez MS, **Skinner HD**, Walker CM, Williams MD, Tailor R, Court LE, Bankson JA, Lai SY. Evaluation of hyperpolarized [1 – ¹³C] – pyruvate by magnetic resonance to detect ionizing radiation effects in real time. *PLoS One* 9(1):e87031, 2014. e – Pub 1/2014. PMCID: PMC3903593.

38. Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, **Skinner HD**. The p53 – Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells. *PLoS One* 9(8):e104821, 2014. e – Pub 8/2014. PMCID: PMC4132078.
39. Castillo R, Pham N, Castillo E, Aso – Gonzalez S, Ansari S, Hobbs B, Palacio D, **Skinner H**, Guerrero TM. Pre – Radiation Therapy Fluorine 18 Fluorodeoxyglucose PET Helps Identify Patients with Esophageal Cancer at High Risk for Radiation Pneumonitis. *Radiology*:140457. 2015 Jun;275(3):822 – 31. e – Pub 1/2015. PMID: 25584706.
40. Fitzgerald AL, Osman AA, Xie TX, Patel A, **Skinner HD**, Sandulache V, Myers JN. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53 – mediated senescence of head and neck cancer cells. *Cell Death Dis* 6:e1678, 3/2015. e – Pub 3/2015. PMCID: PMC4385922.
41. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, **Skinner HD**, Zhao M, Sturgis EM, Kies MS, El – Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. *Cancer Res* 75(7):1205 – 1215, 4/2015. e – Pub 2/2015. PMCID: PMC4615655.
42. Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, **Skinner HD**, Giri U, Sano D, Story MD, Beadle BM, El – Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O. Evolutionary Action Score of TP53 Identifies High – Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. *Cancer Res* 75(7):1527 – 1536, 4/2015. e – Pub 1/2015. PMCID: PMC4383697.
43. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, **Skinner HD**, Johnson RL, Ajani JA. ABT – 263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. *Oncotarget* 6(28):25883 – 25896, 9/2015. PMCID: PMC4694873.
44. Sandulache VC, Hamblin J, Lai S, Pezzi T, **Skinner HD**, Khan NA, Dioun SM, Hartman C, Kramer J, Chiao E, Zhou X, Zevallos JP. Oropharyngeal squamous cell carcinoma (OPSCCA) in the veteran population is associated with traditional carcinogen exposure and poor clinical outcomes. *Head Neck* 37(9):1246 – 1253, 9/2015. e – Pub 7/2015. PMCID: PMC4496314.
45. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, **Skinner HD**, Macapinlac HA, Ajani JA. 18 – fluorodeoxy – glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. *Eur J Cancer* 51(17):2545 – 2552, 11/2015. e – Pub 8/2015. PMCID: PMC4663130.
46. Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, **Skinner HD**, Johnson FM, Myers JN, Osman AA. Wee – 1 Kinase Inhibition Sensitizes High – Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of Mcl – 1 and XIAP Antiapoptotic Proteins. *Clin Cancer Res* 21(21):4831 – 4844, 11/2015. e – Pub 6/2015. PMCID: PMC4631620.
47. Sandulache VC, Chen Y, **Skinner HD**, Lu T, Feng L, Court LE, Myers JN, Meyn RE, Fuller CD, Bankson JA, Lai SY. Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic

Stress: Development of a Biochemical Model. *Mol Cancer Ther* 14(12):2901 – 2908, 12/2015. e – Pub 9/2015. PMCID: PMC4762176.

48. Neishaboori N, Wadhwa R, Nogueras – González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garriss JL, Rice DC, Komaki R, Swisher SG, **Skinner HD**, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. *Oncology* 89(2):65 – 69, 2015. e – Pub 3/2015. PMCID: PMC4498973.
49. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, **Skinner HD**, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality – Eligible Patients with Esophageal Adenocarcinoma. *Oncology* 88(6):332 – 336, 2015. e – Pub 2/2015. PMCID: PMC4449796.
50. Zevallos JP, Sandulache VC, Hamblin J, **Skinner HD**, Kramer J, Hartman CM, Horter KL, Lai S, Zhou X, Chiao EY. Impact of race on oropharyngeal squamous cell carcinoma presentation and outcomes among veterans. *Head Neck* 38(1):44 – 50, 1/2016. e – Pub 1/2015. PMID: 24992520.
51. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, **Skinner HD**, Garriss JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. *J Natl Compr Canc Netw* 14(2):173 – 179, 2/2016. PMID: 26850487.
52. Spratt DE, Beadle BM, Zumsteg ZS, Rivera A, **Skinner HD**, Osborne JR, Garden AS, Lee NY. The influence of diabetes mellitus and metformin on distant metastases in oropharyngeal cancer: A multicenter study. *Int J Radiat Oncol Biol Phys* 94(3):523 – 531, 3/2016. e – Pub 11/2015. PMCID: PMC4993040.
53. Nien HH, Sturgis EM, Kies MS, El – Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, **Skinner H**, Rosenthal DI, Garden AS. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus – associated oropharyngeal cancer. *Head Neck* 38 Suppl 1:E1554 – 1561, 4/2016. e – Pub 11/2015. PMID: 26595157.
54. Woo SH, Yang LP, Chuang HC, Fitzgerald A, Lee HY, Pickering C, Myers JN, **Skinner HD**. Down – regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy – induced senescence. *Head Neck* 38 Suppl 1:E934 – 940, 4/2016. e – Pub 7/2015. PMID: 25994759.
55. Sandulache VC, Vandelaar LJ, **Skinner HD**, Cata J, Hutcheson K, Fuller CD, Phan J, Siddiqui Z, Lai SY, Weber RS, Zafereo ME. Salvage total laryngectomy after external – beam radiotherapy: A 20 – year experience. *Head Neck* Suppl 38:E1962 – 1968, 4/2016. e – Pub 2/2016. PMCID: PMC5300043.
56. Gunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, Morrison WH, Phan J, Beadle BM, **Skinner HD**, Sturgis EM, Kies MS, Hutcheson KA, Rosenthal DI, Mohan R, Gillin MT, Frank SJ. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. *Int J Radiat Oncol Biol Phys* 95(1):360 – 367, 5/2016. e – Pub 2/2016. PMCID: PMC5474303.

57. Grossberg AJ, Chamchod S, Fuller CD, Mohamed AS, Heukelom J, Eichelberger H, Kantor ME, Hutcheson KA, Gunn GB, Garden AS, Frank S, Phan J, Beadle B, **Skinner HD**, Morrison WH, Rosenthal DI. Association of Body Composition With Survival and Locoregional Control of Radiotherapy – treated head and neck squamous cell carcinoma. *JAMA Oncol* 2(6):782 – 789, 6/2016. PMID: PMC5080910.
58. Jiang W, Mohamed AS, Fuller CD, Kim BY, Tang C, Gunn GB, Hanna EY, Frank SJ, Su SY, Diaz E, Kupferman ME, Beadle BM, Morrison WH, **Skinner H**, Lai SY, El – Naggar AK, DeMonte F, Rosenthal DI, Garden AS, Phan J. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. *Pract Radiat Oncol* 6(4):241 – 247, Jul – Aug, 7/2016. e – Pub 11/2015. PMID: PMC5286455.
59. Hoffman KE, **Skinner H**, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient – reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity – modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. *Am J Clin Oncol* 41(6):558 – 567. 6/2018. e – Pub 9/2016. PMID: 27635624.
60. **Skinner HD**, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El – Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer. *Clin Cancer Res* 22(18):4643 – 4650, 9/2016. e – Pub 4/2016. PMID: PMC5061056.
61. Bridges KA, Chen X, Liu H, Rock C, Buchholz TA, Shumway SD, **Skinner HD**, Meyn RE. MK – 8776, a novel chk1 kinase inhibitor, radiosensitizes p53 – defective human tumor cells. *Oncotarget* 7(44):71660 – 71672, 11/2016. e – Pub 9/2016. PMID: PMC5342109.
62. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, **Skinner H**, Lee JH, Weston B, Bhutani MS, Blum – Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long – Term Survivors. *Oncology* 91(1):55 – 60, 2016. e – Pub 4/2016. PMID: PMC4949128.
63. Chadha AS, **Skinner HD**, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I trial of consolidative radiotherapy with concurrent bevacizumab, erlotinib and capecitabine for unresectable pancreatic cancer. *PLoS One* 11(6):e0156910, 2016. e – Pub 6/2016. PMID: PMC4919049.
64. Wang L, Zhang P, Molkentine DP, Chen C, Molkentine JM, Piao H, Raju U, Zhang J, Valdecanas DR, Tailor RC, Thames HD, Buchholz TA, Chen J, Ma L, Mason KA, Ang KK, Meyn RE, **Skinner HD**. TRIP12 as a mediator of human papillomavirus/p16 – related radiation enhancement effects. *Oncogene* 36(6):820 – 828, 2/2017. e – Pub 7/2016. PMID: PMC5434711.
65. Sandulache VC, Chen Y, Feng L, William WN, **Skinner HD**, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. *Oncotarget* 8(11):18154 – 18165, 3/2017. e – Pub 2/2017. PMID: PMC5392315.

66. Quinlan – Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN, Beadle BM, **Skinner HD**, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. *Head Neck* 39(4):633 – 638, 4/2017. e – Pub 12/2016. PMID: 28006086.
67. Weidhaas JB, Harris J, Schaeue D, Chen AM, Chin R, Axelrod R, El – Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen – Tan PF, Trotti A, **Skinner H**, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS – Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* 3(4):483 – 491, 4/2017. e – Pub 12/2016. PMCID: PMC5470422.
68. **Skinner HD**, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL – PI3 Kinase – PD – L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. *Clin Cancer Res* 23(11):2713 – 2722, 6/2017. e – Pub 5/2017. PMCID: PMC5457365.
69. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, **Skinner HD**, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long – Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. *Oncology*. 2017;93(4):243 – 248. e – Pub 7/2017. PMID: 28683449.
70. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, **Skinner HD**, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli – 1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. *Br J Cancer* 117(5):648 – 655, 8/2017. e – Pub 7/2017. PMCID: PMC5572179.
71. Mohamed ASR, Wong AJ, Fuller CD, Kamal M, Gunn GB, Phan J, Morrison WH, Beadle BM, **Skinner H**, Lai SY, Quinlan – Davidson SR, Belal AM, El – Gowily AG, Frank SJ, Rosenthal DI, Garden AS. Patterns of locoregional failure following post – operative intensity – modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. *Radiat Oncol* 12(1):129, 1 – 12, 8/2017. e – Pub 8/2017. PMCID: PMC5557312.
72. Quinlan – Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, **Skinner H**, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. *Oral Oncol* 72:90 – 97, 9/2017. e – Pub 7/2017. PMID: 28797467.
73. Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, **Skinner HD**, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB, MD Anderson Head and Neck Cancer Symptom Working Group. Cognitive function and patient – reported memory problems after radiotherapy for cancers at the skull base: A cross – sectional survivorship study using the Telephone Interview for Cognitive Status

and the MD Anderson Symptom Inventory – Head and Neck Module. *Head Neck* 39(10):2048 – 2056, 10/2017. e – Pub 8/2017. PMID: 28763137.

74. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerckel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, **Skinner HD**, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound – guided fine – needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. *Oncotarget* 8(45):79356 – 79365, 10/2017. e – Pub 5/2017. PMID: PMC5668047.
75. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, **Skinner HD**, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival – The University of Texas MD Anderson Cancer Center experience. *Cancer* 123(21):4106 – 4113, 11/2017. e – Pub 9/2017. PMID: 28885712.
76. Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, **Skinner HD**, Johnson RL, Ding S, Ajani JA. A Novel YAP1 Inhibitor targets CSCs – enriched Radiation Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. *Mol Cancer Ther* 17(2):443 – 454, 2/2018. e – Pub 2/2018. PMID: 29167315.
77. Liu X*, Kumar M*, Yang L, Molkentine DP, Valdacas D, Yu S, Meyn RE, Heymach J, **Skinner HD**. BAP1 is a novel target in HPV negative head and neck cancer. *Clin Cancer Res*, 24(3):600 – 607, 2/2018. PMID: 29113987. (*contributed equally).
78. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, **Skinner HD**, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. *Target Oncol*, 13(1):99 – 106, 2/2018. PMID: 29218623.
79. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, **Skinner HD**, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy – eligible oesophageal cancer patients: secondary analysis of a randomised trial. *Br J Cancer*, 6;118(3):331 – 337, 2/2018. PMID: 29235564.
80. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, **Skinner HD**, Maru DM, Hofstetter WL, Ajani JA. Actionable locoregional relapses after therapy of localized esophageal cancer: Insights from a large cohort. *Oncology* 94(6):345 – 353, 04/27/2018, 4/2018. PMID: 29705797.
81. Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, **Skinner HD**, Rosenthal DI, Garden AS. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity – modulated radiation therapy. *Cancer* 124(7):1415 – 1427, 4/2018. e – Pub 1/2018. PMID: 29338089.
82. Cabanillas M, Ferrarotto R, Garden A, Ahmed S, Busaidy N, Dadu R, Williams MD, **Skinner HD**, Gunn B, Grosu HO, Iyer PC, Hofmann MC, Zafereo M. Neoadjuvant BRAF – and

immune – directed therapy for anaplastic thyroid carcinoma. *Thyroid*, 28(7):945 – 951. 7/2018 PMID: 29742974.

83. Hoffman KE, **Skinner HD**, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient – reported urinary, bowel, and sexual function after hypofractionated intensity – modulated radiation therapy for prostate cancer: Results from a randomized trial. *Am J Clin Oncol* 41(6):558 – 567, 6/2018. PMID: 27635624.
84. Iyer PC, Dadu R, Gule – Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, **Skinner HD**, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. *J Immunother Cancer*. 2018 Jul 11;6(1):68. PMID: 29996921.
85. Ng SP, Johnson JM, Gunn GB, Rosenthal DI, **Skinner HD**, Phan J, Frank SJ, Morrison W, Sturgis EM, Mott FE, Williams MD, Fuller CD, Garden AS. Significance of Negative Posttreatment 18 – FDG PET/CT Imaging in Patients With p16/HPV – Positive Oropharyngeal Cancer. *Int J Radiat Oncol Biol Phys*. 2018 Jun 28. pii:S0360 – 3016(18)31022 – 8. PMID: 29960060.
86. Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, **Skinner HD**, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT – HN): matching 'liquid biopsy' and quantitative tumor modeling. *BMC Cancer*. 2018 Sep 19;18(1):903. PMID: 30231854.
87. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, **Skinner HD**, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA. YAP1 – Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. *Clin Cancer Res*. 2019 Apr 1;25(7):2264 – 2277. Epub 2018 Dec 18. PMID: 30563933.
88. Lin TA, Garden AS, Elhalawani H, Elgohari B, Jethanandani A, Ng SP, Mohamed AS, Frank SJ, Glisson BS, Debnam JM, Sturgis EM, Phan J, Reddy JP, Fuller CD, Morrison WH, **Skinner HD**, Rosenthal DI, Gunn GB. Radiographic retropharyngeal lymph node involvement in HPV – associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. *Cancer*. 2019 May 1;125(9):1536 – 1546. PMID: 30620385.
89. Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre – Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, **Skinner HD**, de Stanchina E, Sidi S. An IRAK1 – PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. *Nat Cell Biol*. 2019 Feb;21(2):203 – 213. PMID: 30664786.
90. Gleber – Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, **Skinner HD**, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. *JCI Insight*. 2019 Jan 10;4(1). pii: 124762. PMID: 30626753.
91. Zhu Y, Mohamed ASR, Lai SY, Yang S, Kanwar A, Wei L, Kamal M, Sengupta S, Elhalawani H, **Skinner H**, Mackin DS, Shiao J, Messer J, Wong A, Ding Y, Zhang L, Court L, Ji Y,

- Fuller CD. Imaging – Genomic Study of Head and Neck Squamous Cell Carcinoma: Associations Between Radiomic Phenotypes and Genomic Mechanisms via Integration of The Cancer Genome Atlas and The Cancer Imaging Archive. *JCO Clin Cancer Inform.* 2019 Feb;3:1 – 9. PMID: 30730765.
92. Ng SP, Pollard C 3rd, Berends J, Ayoub Z, Kamal M, Garden AS, Bahig H, Cantor SB, Schaefer AJ, Ajayi T, Gunn GB, Frank SJ, **Skinner H**, Phan J, Morrison WH, Ferrarotto R, Johnson JM, Mohamed ASR, Lai SY, Hessel AC, Sturgis EM, Weber RS, Fuller CD, Rosenthal DI. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. *Cancer.* 1;125(11):1823 – 1829, 6/2019. PMID: 30748005.
 93. Mohamed ASR, Smith BD, Smith JB, Sevak P, Malek JS, Kanwar A, Browne T, Gunn GB, Garden AS, Frank SJ, Morrison WH, Phan J, Zafereo M, **Skinner H**, Lai SY, Hutcheson KA, Lewin JS, Hessel AE, Thekdi AA, Weber RS, Fuller CD, Rosenthal DI. Outcomes of carotid – sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. *Laryngoscope.* 2019 Feb 12. doi: 10.1002/lary.27873. PubMed PMID: 30756394.
 94. Harms A, Kansara S, Stach C, Richardson PA, Chen G, Lai S, Sikora AG, Parke R, Donovan D, Chiao E, **Skinner H**, Sandulache VC. Swallowing Function in Survivors of Oropharyngeal Cancer Is Associated with Advanced T Classification. *Ann Otol Rhinol Laryngol.* 2019 Mar 27:3489419839091. doi: 10.1177/0003489419839091. PubMed PMID: 30913911.
 95. Fullmer TM, Shi J, **Skinner HD**, Hernandez DJ, Huang AT, Mai W, Parke RB, Donovan DT, Sandulache VC. Early glottic cancer in a veteran population: Impact of race on management and outcomes. *Laryngoscope.* 2019 Aug 28. doi: 10.1002/lary.28262. PMID: 31461171
 96. Ng SP, Pollard C 3rd, Kamal M, Ayoub Z, Garden AS, Bahig H, Gunn GB, Frank SJ, **Skinner HD**, Phan J, Berends J, Morrison WH, Johnson JM, Ferrarotto R, Sturgis EM, Mohamed ASR, Lai SY, Fuller CD, Rosenthal DI. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. *NPJ Precis Oncol.* 2019 Sep 27;3:22. doi: 10.1038/s41698 – 019 – 0097 – y. eCollection 2019. PMID: 31583278, PMCID: PMC6764977.
 97. Nilsen ML, Lyu L, Belsky MA, Mady LJ, Zandberg DP, Clump DA 2nd, **Skinner HD**, Peddada SD, George S, Johnson JT. Impact of Neck Disability on Health – Related Quality of Life among Head and Neck Cancer Survivors. *Otolaryngol Head Neck Surg.* 2020 Jan;162(1):64 – 72. Epub 2019 Oct 15. PMID: 31613686
 98. Ng SP, Bahig H, Jethanandani A, Pollard C, Berends J, Sturgis EM, Johnson FM, Elgohari B, Elhalawani H, Rosenthal DI, **Skinner HD**, Gunn GB, Phan J, Frank SJ, Mohamed ASR, Fuller CD, Garden AS. Lymphopenia during radiotherapy in patients with oropharyngeal cancer. *Radiother Oncol.* 2020 Jan 10;145:95 – 100. [Epub ahead of print] PMID: 31931292
 99. Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, **Skinner HD**. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. *Int J Radiat Biol.* 2020 Feb 25:1 – 8. [Epub ahead of print] PMID: 32073931
 100. Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, **Skinner HD**. Metabolic Responses to Metformin

- in Inoperable Early – stage Non – Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. *Am J Clin Oncol*. 2020 Apr;43(4):231 – 235. PMID: 31990759
101. Dharmarajan H, Anderson JL, Kim S, Sridharan S, Duvvuri U, Ferris RL, Solari MG, Clump DA 2nd, **Skinner HD**, Ohr JP, Zandberg DP, Branstetter B 4th, Hughes MA, Traylor KS, Seethala R, Chiosea SI, Nilsen ML, Johnson JT, Kubik MW. Transition to a virtual multidisciplinary tumor board during the COVID – 19 pandemic: University of Pittsburgh experience. *Head Neck*. 2020 Jun;42(6):1310 – 1316. doi: 10.1002/hed.26195. Epub 2020 Apr 27. PMID: 32329958; PMCID: PMC7264555.
 102. Fullmer T, Wilde DC, Shi JW, Wagner T, **Skinner H**, Eicher SA, Sandulache VC, Hernandez DJ. Demographic and Tumor Characteristic Impact on Laryngeal Cancer Outcomes in a Minority Underserved Patient Population. *Otolaryngol Head Neck Surg*. 2020 Jun;162(6):888 – 896. doi: 10.1177/0194599820907064. Epub 2020 Feb 25. PMID: 32093532.
 103. Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, **Skinner HD**. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. *Int J Radiat Biol*. 2020 Feb 25:1 – 8. doi: 0.1080/09553002.2020.1730014. Epub ahead of print. PMID: 32073931.
 104. Frederick M, **Skinner HD**, Kazi SA, Sikora AG, Sandulache VC. High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung. *Sci Rep*. 2020 Apr 14;10(1):6380. doi:10.1038/s41598 – 020 – 63448 – z. PMID: 32286489; PMCID: PMC7156383.
 105. Uzunparmak B, Gao M, Lindemann A, Erikson K, Wang L, Lin E, Frank SJ, Gleber – Netto FO, Zhao M, Skinner HD, Newton JM, Sikora AG, Myers JN, Pickering CR. Caspase 8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic induced necroptosis. *JCI Insight* [Internet]. 2020; Available from: <https://doi.org/10.1172/jci.insight.139837>
 106. Nilsen ML, Belsky MA, Scheff N, Johnson JT, Zandberg DP, **Skinner H**, Ferris R. Late and Long – Term Treatment – Related Effects and Survivorship for Head and Neck Cancer Patients. *Curr Treat Options Oncol*. 2020 Oct 3;21(12):92. doi: 10.1007/s11864 – 020 – 00797 – x. PMID: 33009956.
 107. Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, **Skinner HD**, Timmerman J, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th – 5th, 2019, Naples, Italy). *J Transl Med*. 2021 Jan 6;19(1):13. doi: 10.1186/s12967 – 020 – 02627 – y. PMID: 33407605; PMCID: PMC7789268.
 108. Veeramachaneni R, Yu W, Newton JM, Kemnade JO, **Skinner HD**, Sikora AG, Sandulache VC. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. *J Immunother Cancer*. 2021 Jul;9(7):e002773. doi: 10.1136/jitc – 2021 – 002773. PMID: 34230113.
 109. Cardenas CE, Beadle BM, Garden AS, **Skinner HD**, Yang J, Rhee DJ, McCarroll RE, Netherton TJ, Gay SS, Zhang L, Court LE. Generating High – Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated

- Deep Learning – Based Approach. *Int J Radiat Oncol Biol Phys*. 2021 Mar 1;109(3):801 – 812. doi: 10.1016/j.ijrobp.2020.10.005. Epub 2020 Oct 14. PMID: 33068690.
110. Prabhu AV, Bimali M, Miljanic M, Kay H, Sandow L, Zhang M, Mumford K, Shah D, Clump DA, **Skinner HD**, Lewis GD. The Use of Crowdfunding to Support Radiation Therapy Cancer Treatments. *Anticancer Res*. 2021 Aug;41(8):3759 – 3767. doi: 10.21873/anticancer.15168. PMID: 34281835.
 111. **Skinner H**, Hu C, Tsakiridis T, Santana – Davila R, Lu B, Erasmus JJ, Doemer AJ, Videtic GMM, Coster J, Yang AX, Lee RY, Werner – Wasik M, Schaner PE, McCormack SE, Esparaz BT, McGarry RC, Bazan J, Struve T, Paulus R, Bradley JD. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non – Small Cell Lung Cancer: The NRG – LU001 Phase 2 Randomized Clinical Trial. *JAMA Oncol*. 2021 Sep 1;7(9):1324 – 1332. doi: 10.1001/jamaoncol.2021.2318. PMID: 34323922; PMCID: PMC8323052.
 112. Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, **Skinner HD**. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. *Nat Commun*. 2021 Nov 3;12(1):6340. PMID: 34732714.
 113. Molkentine DP, Molkentine JM, Bridges KA, Valdecanas DR, Dhawan A, Bahri R, Hefner AJ, Kumar M, Yang L, Abdelhakiem M, Pifer PM, Sandulache V, Sheth A, Beadle BM, Thames HD, Mason KA, Pickering CR, Meyn RE, **Skinner HD**. p16 Represses DNA Damage Repair via a Novel Ubiquitin – Dependent Signaling Cascade. *Cancer Res*. 2022 Mar 1;82(5):916 – 928. doi: 10.1158/0008 – 5472.CAN – 21 – 2101. PMID: 34965932.
 114. Wilde DC, Castro PD, Bera K, Lai S, Madabhushi A, Corredor G, Koyuncu C, Lewis JS Jr, Lu C, Frederick MJ, Frederick AM, Haugen AE, Zevallos JP, Sturgis EM, Shi J, Huang AT, Hernandez DJ, **Skinner HD**, Kemnade JO, Yu W, Sikora AG, Sandulache VC. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. *Mod Pathol*. 2022 Feb 18. doi: 10.1038/s41379 – 022 – 01024 – 8. Epub ahead of print. PMID: 35184149.
 115. Cao W, Gronberg M, Olanrewaju A, Whitaker T, Hoffman K, Cardenas C, Garden A, **Skinner H**, Beadle B, Court L. Knowledge-based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer. *J Appl Clin Med Phys*. 2022 Jun;23(6):e13614. doi: 10.1002/acm2.13614. Epub 2022 Apr 30. PMID: 35488508; PMCID: PMC9195018.
 116. Borson S, Shuai Y, Branstetter BF, Nilsen ML, Hughes MA, Fenton M, Kubik M, Sridharan S, Clump DA, **Skinner HD**, Johnson JT, Chiosea SI, Ohr J, Duvvuri U, Kim S, Traylor KS, Ferris R, Zandberg DP. Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis. *Laryngoscope Invest Otolaryngol*. 2022 May 6;7(3):757-765. doi: 10.1002/lio2.807. PMID: 35734044; PMCID: PMC9194988.
 117. Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, **Skinner HD**, Pickering CR, Myers JN, Rai K. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. *Front Cell Dev Biol*. 2022 Jul 19;10:936168. doi: 10.3389/fcell.2022.936168. PMID: 35927986; PMCID: PMC9343809.

118. Rodriguez CP, Kang H, Geiger JL, Burtneess B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, **Skinner H**, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. *J Natl Cancer Inst.* 2022 Dec 8;114(12):1619-1627. doi: 10.1093/jnci/djac163. PMID: 36053203; PMCID: PMC9745425.
119. Gronberg MP, Beadle BM, Garden AS, **Skinner H**, Gay S, Netherton T, Cao W, Cardenas CE, Chung C, Fuentes DT, Fuller CD, Howell RM, Jhingran A, Lim TY, Marquez B, Mumme R, Olanrewaju AM, Peterson CB, Vazquez I, Whitaker TJ, Wooten Z, Yang M, Court LE. Deep Learning-Based Dose Prediction for Automated, Individualized Quality Assurance of Head and Neck Radiation Therapy Plans. *Pract Radiat Oncol.* 2023 Jan 23:S1879-8500(22)00388-5. doi: 10.1016/j.prro.2022.12.003. Epub ahead of print. PMID: 36697347.
120. Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, **Skinner HD**, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. *Br J Cancer.* 2023 Jun;128(11):2013-2024. doi: 10.1038/s41416-023-02253-7. Epub 2023 Apr 3. PMID: 37012319
121. Kemnade JO, Florez M, Sabichi A, Zhang J, Jhaveri P, Chen G, Chen A, Miller-Chism C, Shaun B, Hilsenbeck SG, Hernandez DJ, **Skinner HD**, Sandulache VC. Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. *Oral Oncol.* 2023 Oct;145:106536. doi: 10.1016/j.oraloncology.2023.106536. Epub 2023 Aug 8. PMID: 37562095
122. Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, Beadle B, Molkentine D, Molkentine J, Dhawan A, Abdelhakiem M, Osman AA, Leibowitz BJ, Myers JN, Pickering CR, Sandulache VC, Heymach J, **Skinner HD**. FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner. *Clin Cancer Res.* 2023 Oct 11. doi: 10.1158/1078-0432.CCR-23-0964. Epub ahead of print. PMID: 37819945.
123. Luke JJ, Dadey RE, Augustin RC, Newman S, Singh KB, Doerfler R, Behr S, Lee P, Isett B, Deitrick C, Li A, Joy M, Reeder C, Smith K, Urban J, Sellitto L, Jelinek M, Christner SM, Beumer JH, Villaruz LC, Kulkarni A, Davar D, Poklepovic AS, Najjar Y, Zandberg DP, Soloff AC, Bruno TC, Vujanović L, **Skinner HD**, Ferris RL, Bao R. Tumor cell p38 inhibition to overcome immunotherapy resistance. *Res Sq [Preprint].* 2023 Aug 19:rs.3.rs-3183496. doi: 10.21203/rs.3.rs-3183496/v1. PMID: 37645831; PMCID: PMC10462255.
124. Karapetyan L, Iheagwara UK, Olson AC, Chmura SJ, **Skinner HD**, Luke JJ. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. *J Natl Cancer Inst.* 2023 Nov 8;115(11):1278-1293. doi: 10.1093/jnci/djad118. PMID: 37348864; PMCID: PMC10637035.
125. Suter P, **Skinner H**, Witek M, Mishra M, Kwok Y, Davicioni E, Feng F, Song D, Nichols E, Tran PT, Bergom C. Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. *Semin Radiat Oncol.* 2023 Jul;33(3):232-242. doi: 10.1016/j.semradiatonc.2023.03.001. PMID: 37331778; PMCID: PMC10446901.
126. Tate MK, Hernandez M, Chang JY, Lin SH, Liao Z, Koshy SM, **Skinner HD**, Chun SG. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell

Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. *Anticancer Res.* 2024 Jan;44(1):133-137. doi: 10.21873/anticancer.16795. PMID: 38159979; PMCID: PMC11663441.

127. Abdelhakiem MK, Bao R, Pifer PM, Molkentine D, Molkentine J, Hefner A, Beadle B, Heymach JV, Luke JJ, Ferris RL, Pickering CR, Wang JH, Patel RB, **Skinner HD**. Th2 Cells Are Associated with Tumor Recurrence Following Radiation. *Cancers (Basel)*. 2024 Apr 20;16(8):1586. doi: 10.3390/cancers16081586. PMID: 38672668; PMCID: PMC11049347.
128. Zandberg DP, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, Anderson JL, Delgoffe GM, Menk A, **Skinner HD**, Duvvuri U, Ferris RL, Colen RR. Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. *Head Neck*. 2025 Jan;47(1):129-138. doi: 10.1002/hed.27878. Epub 2024 Jul 30. PMID: 39080968; PMCID: PMC11635745.
129. Contrera KJ, Spector ME, Pantanowitz L, Abukhiran IM, Vujanovic L, Whiteside TL, Mowery YM, Zandberg DP, Sriharan SS, Kim S, Wilke C, **Skinner HD**, Zevallos JP, Ferris RL. CD8⁺ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: A Review. *JCO Precis Oncol*. 2024 Oct;8:e2400183. doi: 10.1200/PO.24.00183. Epub 2024 Nov 20. PMID: 39565979.
130. Chowdhury MAK, Biswas T, Rahman T, Salma O, Mizana, **Skinner HD**, Avery S, Ngwa W, Huq MS. Cancer prevention, care, and outreach among the Rohingya refugee population in Bangladesh. *Lancet Oncol*. 2024 Dec;25(12):1533-1536. doi: 10.1016/S1470-2045(24)00631-4. PMID: 39637886.
131. Huq MS, Acharya SC, Sharma S, Poudyal S, Sapkota S, Shrestha S, Gautam M, Silwal SR, Haque MM, Uddin AFMK, Gunasekara S, Babu KG, Tshomo U, Safi AJ, Masood AI, Sumon MA, Hai MA, Hossain A, Purvin S, **Skinner HD**, Avery S, Ngwa W, Wijesooriya K. Cancer care and outreach in South Asian Association for Regional Cooperation (SAARC) countries: from epidemiology and the National Cancer Control Programme to screening, diagnosis, and treatment. *Lancet Oncol*. 2024 Dec;25(12):e639-e649. doi: 10.1016/S1470-2045(24)00521-7. PMID: 39637901.
132. Huq MS, Acharya SC, Poudyal S, Sharma S, Silwal SR, Sapkota S, Gautam M, Haque MM, Uddin AFMK, Gunasekara S, Babu KG, Tshomo U, Safi AJ, Masood AI, Sumon MA, Purvin S, Hai MA, **Skinner HD**, Avery S, Ngwa W, Wijesooriya K. Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges. *Lancet Oncol*. 2024 Dec;25(12):e650-e662. doi: 10.1016/S1470-2045(24)00514-X. PMID: 39637902.
133. Huq MS, Acharya SC, Sapkota S, Silwal SR, Gautam M, Sharma S, Poudyal S, Sumon MA, Hossain T, Uddin AFMK, Gunasekara S, Babu KG, Malhotra H, Tshomo U, Safi AJ, Masood AI, Purvin S, Hai MA, Islam SM, Islam T, **Skinner HD**, Avery S, Ngwa W, Wijesooriya K. Cancer education and training within the South Asian Association for Regional Cooperation (SAARC) countries. *Lancet Oncol*. 2024 Dec;25(12):e663-e674. doi: 10.1016/S1470-2045(24)00517-5. PMID: 39637903.
134. Huq MS, Acharya SC, Gautam M, Silwal SR, Sapkota S, Poudyal S, Sharma S, Babu KG, Nigar T, Pervin S, Gulia S, Gunasekara S, Uddin AFMK, Tshomo U, Safi AJ, Nadeem MS, Masood AI, Sumon MA, Purvin S, Hai MA, **Skinner HD**, Avery S, Ngwa W, Wijesooriya K. Cancer research in South Asian Association for Regional Cooperation (SAARC) countries.

Lancet Oncol. 2024 Dec;25(12):e675-e684. doi: 10.1016/S1470-2045(24)00518-7. PMID: 39637904.

135. Gopalkrishnan A, Wang N, Cruz-Rangel S, Yassin-Kassab A, Shiva S, Kurukulasuriya C, Monga SP, DeBerardinis RJ, **Skinner HD**, Kiselyov K, Duvvuri U. Lysosomal/mitochondrial interaction promotes tumor growth in squamous cell carcinoma of the head and neck. *Mol Cancer Res.* 2024 Dec 19. doi: 10.1158/1541-7786.MCR-24-0337. Epub ahead of print. PMID: 39699311.
136. Zandberg DP, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, Anderson JL, Delgoffe GM, Menk A, Skinner HD, Duvvuri U, Ferris RL, Colen RR. Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. *Head Neck.* 2025 Jan;47(1):129-138. doi: 10.1002/hed.27878. Epub 2024 Jul 30. PMID: 39080968; PMCID: PMC11635745.
137. Hsieh RW, Gooding WE, Nilsen M, Kubik M, Kelly Z, Sridharan S, Skinner H, Iheagwara U, Zevallos JP, Duvvuri U, Kim S, Ferris RL, Zandberg DP. Association of Patient and Tumor Characteristics With Outcomes in Young Head and Neck Squamous Cell Carcinoma Patients. *Clin Otolaryngol.* 2025 Jan;50(1):15-21. doi: 10.1111/coa.14215. Epub 2024 Aug 22. PMID: 39175141; PMCID: PMC11618290.
138. Gopalkrishnan A, Wang N, Cruz-Rangel S, Yassin-Kassab A, Shiva S, Kurukulasuriya C, Monga SP, DeBerardinis RJ, Skinner HD, Kiselyov K, Duvvuri U. Lysosomal-Mitochondrial Interaction Promotes Tumor Growth in Squamous Cell Carcinoma of the Head and Neck. *Mol Cancer Res.* 2025 Apr 1;23(4):339-349. doi: 10.1158/1541-7786.MCR-24-0337. PMID: 39699311; PMCID: PMC11961326.
139. Contrera KJ, Reddy PD, Helou V, Myers JN, Skinner HD, Ferrarotto R, Myers EN. The Evolution of Multidisciplinary Head and Neck Cancer Treatment. *Laryngoscope.* 2025 Jul;135(7):2255-2260. doi: 10.1002/lary.32064. Epub 2025 Feb 17. PMID: 39960134; PMCID: PMC12230886.
140. Sobti A, Skinner H, Wilke CT. Predictors of Radiation Resistance and Novel Radiation Sensitizers in Head and Neck Cancers: Advancing Radiotherapy Efficacy. *Semin Radiat Oncol.* 2025 Apr;35(2):224-242. doi: 10.1016/j.semradonc.2025.02.008. PMID: 40090749.
141. Li Y, Yadollahi P, Essien FN, Putluri V, Ambati CSR, Kami Reddy KR, Kamal AHM, Putluri N, Abdurrahman LM, Ruiz Echartea ME, Ernste KJ, Trivedi AJ, Vazquez-Perez J, Hudson WH, Decker WK, Patel R, Osman AA, Kheradmand F, Lai SY, Myers JN, Skinner HD, Coarfa C, Lee K, Jain A, Malovannaya A, Frederick MJ, Sandulache VC. Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. *J Transl Med.* 2025 Apr 5;23(1):403. doi: 10.1186/s12967-025-06258-z. PMID: 40188338; PMCID: PMC11971752.
142. Frederick MJ, Perez-Bello D, Yadollahi P, Castro P, Frederick A, Frederick A, Osman RA, Essien F, Yebra I, Hamlin A, Ow TJ, Skinner HD, Sandulache VC. Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research. *PLoS One.* 2025 Apr 21;20(4):e0321631. doi: 10.1371/journal.pone.0321631. PMID: 40258023; PMCID: PMC12011225.
143. Zandberg DP, Vujanovic L, Clump DA, Isett BP, Wang H, Sica G, Bao R, Li H, Ohr J, Skinner HD, Seethala RR, Chiosea SI, Ferris RL, Bauman JE. Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in

- Locally Advanced Head and Neck Cancer. *J Clin Oncol*. 2025 Aug 10;43(23):2572-2582. doi: 10.1200/JCO-24-01580. Epub 2025 May 27. PMID: 40424564; PMCID: PMC12316147.
144. Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. *Br J Cancer*. 2025 Dec;133(12):1802-1814. doi: 10.1038/s41416-025-03189-w. Epub 2025 Oct 6. PMID: 41053162; PMCID: PMC12690143.
 145. Helou V, Abdul-Rahman NH, Loo SK, Gao SJ, Zevallos JP, Zandberg DP, Spector ME, Skinner HD, Ferris RL, Contrera KJ. Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis. *Oral Oncol*. 2025 Nov;170:107760. doi: 10.1016/j.oraloncology.2025.107760. Epub 2025 Oct 17. PMID: 41108912.
 146. Doerfler R, Chen J, Kim C, Smith JD, Harris M, Singh KB, Isett B, Dadey RE, Brown DD, Lee AV, Wang X, Spector ME, Kim S, Sridharan S, Contrera K, Smith K, Reeder C, Lyons M, Luo J, Liu S, Zandberg DP, Skinner HD, Zervantonakis IK, Vujanović L, Ferris RL, Seethala RR, Zevallos JP, Luke JJ, Bao R. Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer. *Oral Oncol*. 2025 Dec;171:107742. doi: 10.1016/j.oraloncology.2025.107742. Epub 2025 Nov 9. PMID: 41213213.

ABSTRACTS:

More than 80 abstracts at national scientific meetings.

OTHER NON – PEER REVIEWED PUBLICATIONS:

INVITED ARTICLES:

1. **Skinner HD**, Krishnan S. Predicting, preventing, treating and understanding radiation nephropathy. *J Gastrointest Oncol* 1(1):2 – 4, 9/2010.
2. **Skinner HD**, Hong T, Krishnan S. Charged particle therapy for hepatocellular carcinoma. *Semin Radiat Oncol* 21(4):278 – 286, 2011.
3. **Skinner HD**, Holsinger FC, Beadle BM. Oropharynx cancer. *Curr Probl Cancer* 36(6):334 – 415, 12/2012.
4. Ow TJ, Sandulache VC, **Skinner HD**, Myers JN. Integration of cancer genomics with treatment selection: from genome to predictive biomarkers. *Cancer*, 8/2013. e – Pub .
5. Blum MA, Taketa T, Sudo K, Wadhwa R, **Skinner HD**, Ajani JA. Chemoradiation for esophageal cancer. *Thorac Surg Clin* 23(4):551 – 558, 11/2013. PMID: 24199704.
6. Woo SH, Sandulache VC, Yang L, **Skinner HD**. Evaluating Response to Metformin/Cisplatin Combination in Cancer Cells via Metabolic Measurement and Clonogenic Survival. *Methods Mol Biol* 1165:11 – 18, 2014. PMID: 24839015.
7. Sandulache VC, Yang L, **Skinner HD**. Use of biguanides to improve response to chemotherapy. *Methods Mol Biol* 1165:3 – 9, 2014. PMID: 24839014.

8. Meyn RE, Krishnan S, **Skinner HD**. Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer. *Clin Cancer Res* 22(8):1834 – 1836, 4/2016. e – Pub 2/2016. PMID: PMC5061034.
9. Clump DA, Pickering CR, **Skinner HD**. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. *Clin Cancer Res*. 2019 Mar1;25(5):1441 – 1442. doi: 10.1158/1078 – 0432.CCR – 18 – 3078. Epub 2018 Nov 9. PubMed PMID: 30413524; PubMed Central PMCID: PMC6415532.
10. Bibee K, Swartz A, Sridharan S, Kurten CHL, Wessel CB, **Skinner H**, Zandberg DP. Cutaneous squamous cell carcinoma in the organ transplant recipient. *Oral Oncol*. 2020 Apr;103:104562. doi: 10.1016/j.oraloncology.2019.104562. Epub 2020 Feb 14. PMID: 32065978; PMCID: PMC7217490.
11. Kubik MW, Sridharan S, Varvares MA, Zandberg DP, **Skinner HD**, Seethala RR, Chiosea SI. Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse? *Head Neck Pathol*. 2020 Jun;14(2):291 – 302. doi: 10.1007/s12105 – 019 – 01121 – 2. Epub 2020 Mar 2. PMID: 32124417; PMCID: PMC7235105.
12. Zandberg D, **Skinner HD**, Ferris RL. Expert editorial on: KEYNOTE – 048: A Phase III Study of First – Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Internet]. *ASCO Daily News*. Available from: <https://dailynews.ascopubs.org/do/10.1200/ADN.19.190258/full/>
13. Sandulache VC, Beadle BM, **Skinner HD**. Therapeutic De – escalation in HPV – positive Head and Neck Cancer. *ASCO Daily News*. Sept 3, 2020. Available from: <https://dailynews.ascopubs.org/do/10.1200/ADN.20.200316/full/>
14. SBRT for early – stage NSCLC: Is it essential to target the unseen disease? Hima Bindu Musunuru, Heath Skinner, Tyler Wilhite. *ASCO Daily News*. Sept. 28, 2022 <https://dailynews.ascopubs.org/do/stereotactic-body-radiotherapy-early-stage-non-small-cell-lung-cancer-essential-target>
15. Dhawan A, Pifer PM, Sandulache VC, **Skinner HD**. Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here? *Front Oncol*. 2022 Dec 14;12:1016217. doi: 10.3389/fonc.2022.1016217. PMID: 36591457; PMCID: PMC9794617.
16. Suter P, **Skinner H**, Witek M, Mishra M, Kwok Y, Davicioni E, Feng F, Song D, Nichols E, Tran PT, Bergom C. Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. *Semin Radiat Oncol*. 2023 Jul;33(3):232-242. doi: 10.1016/j.semradonc.2023.03.001. PMID: 37331778 Review.
17. Karapetyan L, Iheagwara UK, Olson AC, Chmura SJ, **Skinner H**, Luke JJ. Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations. *J Natl Cancer Inst*. 2023 Jun 22:djad118. doi: 10.1093/jnci/djad118. Online ahead of print. PMID: 37348864
18. Patel R, Diego E, Kim H, Berg WA, Bhargava R, Wang H, Sabih Q, McAuliffe P, Brufsky A, Foldi J, Puhalla S, Kane K, Balic M, Edinger B, Wu S, Skinner H, Barry P. Interim Analysis of Dose-Escalated Preoperative Breast Irradiation: A Phase Ib study. *medRxiv [Preprint]*. 2025 Sep 2:2025.08.29.25334741. doi: 10.1101/2025.08.29.25334741. PMID: 40950436; PMCID: PMC12425043.
19. Doerfler R, Chen J, Kim C, Smith JD, Harris M, Singh KB, Isett B, Dadey RE, Brown DD, Lee AV, Wang X, Spector ME, Kim S, Sridharan S, Contrera K, Smith K, Reeder C, Lyons

M, Luo J, Liu S, Zandberg DP, Skinner HD, Zervantonakis IK, Vujanović L, Ferris RL, Seethala RR, Zevallos JP, Luke JJ, Bao R. Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck Cancer. *bioRxiv* [Preprint]. 2025 Aug 7:2025.06.24.660824. doi: 10.1101/2025.06.24.660824. Update in: *Oral Oncol*. 2025 Dec;171:107742. doi: 10.1016/j.oraloncology.2025.107742. PMID: 40667087; PMCID: PMC12262215.

LETTERS TO THE EDITOR:

1. Sudo K, Elimova E, **Skinner HD**, Hofstetter WL, Ajani JA. Reply to R. Gertler et al. *J Clin Oncol* 32(19):2112 – 2113, 7/2014. e – Pub 5/2014. PMID: 24868018.
2. Tsakiridis T, **Skinner H**, Pond G, Swaminath A, Wright J. Metformin for chemo – radio – sensitization of NSCLC. *Radiother Oncol* 120(2):363 – 364, 8/2016. e – Pub 7/2016. PMID: 27401403.

BOOK CHAPTERS:

1. **Skinner HD**, Deorukhkar AA, Krishnan S. Molecular basis of cancer radiation treatment. In: *Principles of Molecular Diagnostics and Personalized Cancer Medicine*, 1st. Ed(s) D Tan, HT Lynch. Lippincott Williams & Wilkins: Philadelphia, 646 – 654, 2013.
2. Manon RR, Myers JN, **Skinner HD**, Harari P. Oral cavity cancer. In: *Principles and Practice of Radiation Oncology*, 6th. Ed(s) EC Halperin, Wazer DE, Perez CA, Brady LW. Lippincott Williams & Wilkins: Philadelphia, 795 – 816, 2013.
3. **Skinner HD**, Komaki R. Radiotherapy: patient selection and clinical outcomes. In: *Personalized Management of Lung Cancer*, 1st. Future Medicine: London, 76 – 86, 2013.
4. **Skinner HD**, Chang JY, Cox JD. Individualized radiotherapy dose escalation and acceleration in lung cancer. In: *Lung Cancer 4th edition*. Ed(s) Roth JA, Hong WK, Komaki R, Tsao AS, Chang JY, Blackmon SH. Wiley – Blackwell. 379 – 389.
5. **Skinner HD**, Chen Q, Elimova E, Wadhwa R, Song S, Ajani JA. Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract. In: *Biomarkers in Cancer Screening and Early Detection*, 1st Edition. Ed Srivastava S. John Wiley & Sons. 118 – 129.
6. Chun SG, **Skinner HD**, Minsky BD. Radiation therapy for locally advanced esophageal cancer. In: *Surg Oncol Clin N Am*, 3rd Edition. Ed(s) Sharms P, Sampliner R, Cutsem EV. Wiley – Blackwell, 257 – 276, e – Book 2017.
7. Khosravi N, **Skinner HD**, Heymach J. FAK as a Target for Therapy in Head and Neck Cancer. In: *Molecular Determinants of Head and Neck Cancer*, 1st Edition Burtneiss B, Golemis EA. Humana Press (Springer), 469 – 490, 2018

PODCASTS:

1. Dr. **Heath Skinner** Discusses Treatment Options for Head and Neck Cancer. *ASCO Daily News*. 1/23/2020

RESEARCH

GRANTS SUBMITTED:

	Targeting Focal Adhesion Kinase in TP53 mutant head and neck cancer	Principal Investigator (MPI) (20%, 2.4 calendar months)	7/1/2024 – 6/30/2029	NIH/NIDCR
--	---	---	----------------------	-----------

CURRENT GRANT SUPPORT:

P50CA097190 – 16	Head and Neck Cancer SPORE	Principal Investigator (MPI) (20%, 2.4 calendar months)	7/1/2022 – 6/30/2027	NIH/NCI \$1,400,000/year
R01DE028061 – 01A1	Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma	Principal Investigator (MPI) (10%, 1.2 calendar months)	4/1/2019 – 3/31/2024	NIH/NIDCR \$385,502/year
R01 DE032337 – 01	Targeting non – canonical p16 signaling to improve radiation response and outcome in head and neck cancer.	Principal Investigator (20%, 2.4 calendar months)	6/15/2023 – 5/31/2028	NIH/NIDCR \$427,896
UG1CA233184 – 01	NCI NCTN – Network Lead Academic Participating Site at UPMC Hillman Cancer Center	Co – Investigator (7.5 %, 0.90 calendar months)	05/01/2019 – 2/29/2025	NIH/NCI \$582,157
R01DE031729-01A1	Immune Exclusion in Cancer Immunotherapy	Co – Investigator (4.5%, 0.55 calendar months)	09/01/2022 – 07/31/2027	NIH/NIDCR \$604,941/year

PRIOR GRANT SUPPORT:

R01DE028105 – 01A1	Enhancing immune mediated head and neck cancer anti – tumor activity using nanoparticles	Principal Investigator (MPI) (12%, 1.44 calendar months)	1/1/2019 – 12/31/2023	NIH/NIDCR \$324,127/year
--------------------	--	--	-----------------------	--------------------------

R01CA168485 – 08	Extension of Radiotherapy Research	Principal Investigator (15%, 1.8 calendar months)	3/1/2017 – 2/28/2022 (NCE)	NIH/NCI \$324,482/year
P30CA47904 Supplement	Cancer Center Support Grant: Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research	Co – Investigator (5%, 0.6 calendar months)	08/01/2020 – 07/31/2021	NIH/NCI \$200,000/year
1U01DE025181	Translating genomic alterations into novel therapeutic targets in head and neck cancer through computational and functional approaches	Co – Investigator (5%, 0.6 calendar months)	7/1/2015 – 4/30/2019	NIH/NIDCR \$957,000/year
NA	Improving head and neck carcinoma radiation therapy through preclinical integration of genomics, radiomics, and novel therapies	Principal Investigator (5%, 0.6 calendar months)	9/1/2016 – 9/7/2018	UT MDACC Multidisciplinary Research Program \$100,000/year
RP150293	Identification of clinically relevant targets for radiosensitization	Principal Investigator (15%, 1.8 calendar months)	3/1/2015 – 8/31/2018	The Cancer Prevention Institute of Texas (CPRIT) \$299,760/year
P50 CA097007 (Career Development Award)	Targeting AMPK in radioresistant mutant TP53 head and neck cancer	Principal Investigator (5%, 0.6 calendar months)	8/1/2012 – 7/31/2014	NIH/NCI \$75,000
NA	Towards Personalized Therapy for Squamous Cell Carcinomas of the Aerodigestive Tract by Overcoming the Oncogenic Functions of p53 Mutation	Co – Investigator (1%, 0.12 calendar months)	4/1/2013 – 3/31/2017	UT MDACC Multidisciplinary Research Program \$100,000/year
NA	Biology and targetability of caspase – 8 mutations in radioresistance of head and neck squamous cell carcinoma	Principal Investigator (10%, 1.2 calendar months)	2/15/2014 – 2/14/2015	Institutional Research Grant, UTMDACC \$50,000

NA	Integrated Genomic and Proteomic Analysis of Recurrent Radiation –Treated Laryngeal Squamous Cell Carcinoma	Principal Investigator (1%, 0.12 calendar months)	7/1/2014 – 6/30/2015	Center for Radiation Oncology Research Grant, UTMDACC
1R21CA182964 – 01A1	Tumor mutation status will predict metabolic response to metformin in NSCLC (Clinical Trial)	Principal Investigator (10%, 1.2 calendar months)	9/1/2014 – 8/31/2017	NIH/NCI